Clover Biopharmaceuticals, Inc.
B-A10 Room No.1, Mansion
Chengdu Hi-tech Zone Hi-tech Incubation Park
Tianhe Incubator, Nan Yan Xian Tian Fu Avenue
Chengdu
610041
China
Tel: 028-85336966
Fax: 028-85336933
Website: http://www.cloverbiopharma.com/
Email: jiang.pu@cloverbiopharma.com
About Clover Biopharmaceuticals, Inc.
Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.
LEADERSHIP:
Founders: Peng Liang, Xiaodong Wang and Jianwei Zhu
CSO: Joshua Liang
COO: Zheng Ping
CIO: Pu Jiang
CLINICAL TRIAL:
95 articles about Clover Biopharmaceuticals, Inc.
-
Clover dosed the first participants in a Phase III study of its COVID-19 booster shot, while Global Access Diagnostics, Orbit Discovery, Proximie and more provide business and pipeline updates.
-
Clover Doses First Patient with SCB-219M in Phase 1 Trial for Chemotherapy-Induced Thrombocytopenia
6/14/2022
Clover Biopharmaceuticals, Ltd. announced that the first patient has been dosed with SCB-219M, an innovative thrombopoietin receptor agonist mimetic Fc-fusion protein, in a Phase 1 clinical trial to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and efficacy of SCB-219M in cancer patients with chemotherapy-induced thrombocytopenia.
-
Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines
6/14/2022
Clover Biopharmaceuticals, Ltd. announced the first participants have been dosed in a Phase 3 study evaluating the safety and immunogenicity of Clover’s SCB-2019 vaccine candidate as a COVID-19 booster in individuals who previously vaccinated with CoronaVac™, Comirnaty®, or Vaxzevria®.
-
Clover to Participate in Credit Suisse Asia Healthcare Corporate Day
6/7/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced its participation in Credit Suisse’s Asia Healthcare Corporate Day, June 14-16, 2022.
-
Clover Provides Update on 2022 Corporate Milestones
6/5/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, provided an update on 2022 corporate milestones.
-
Clover Doses First Participants in Phase 1 Trial with SCB-2020S, a Potentially Broadly Protective Chimeric COVID-19 Vaccine Candidate
5/31/2022
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced the first participants have been dosed in a Phase 1 clinical trial to assess the safety and immunogenicity of several formulations of SCB-2020S.
-
Clover to Participate in Morgan Stanley Virtual China Summit 2022
5/17/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced its participation in Morgan Stanley’s Virtual China Summit, May 24-26, 2022.
-
Clover’s Bivalent COVID-19 Vaccine Candidate Demonstrates Broad Neutralization Against Omicron and Other Variants of Concern
5/5/2022
Clover Biopharmaceuticals, Ltd. announced new promising data from a preclinical study on Clover’s bivalent vaccine candidate, which combines the trimeric spike antigens from the original SARS-CoV-2 strain and the Omicron variant.
-
Clover Appoints LiongHo Chua as President of Greater China
4/27/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced the appointment of Mr. LiongHo Chua as President of Greater China.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
Clover’s Efficacy Data in Previously-Infected Individuals is Published in Lancet Infectious Disease
4/20/2022
Clover Biopharmaceuticals, Ltd. today announced additional data from SPECTRA, a global pivotal Phase 2/3 clinical trial, that shows SCB-2019 (CpG 1018/Alum) provides significant incremental protection against COVID-19.
-
Clover Presents Updated Durability and Booster Data for COVID-19 Vaccine Candidate at World Vaccine Congress Washington 2022
4/19/2022
Clover Biopharmaceuticals, Ltd. today announced additional positive data from two ongoing studies evaluating SCB-2019 (CpG 1018/Alum).
-
Clover To Present at World Vaccine Congress Washington 2022
4/12/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced that Igor Smolenov, Senior Vice President, Global Clinical Development, will deliver a presentation at the World Vaccine Congress Washington 2022.
-
Clover Reports Full Year 2021 Financial Results
3/29/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, reported financial results for the year ended December 31, 2021.
-
Clover’s COVID-19 Vaccine Candidate Demonstrates Durable High Protection and Immune Responses Against Omicron as a Booster
3/17/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced positive clinical results from several studies evaluating Clover’s COVID-19 vaccine candidate, SCB-2019, including follow-up efficacy at five months following primary vaccination and immune responses after a booster dose.
-
Clover to Participate at Upcoming Investor Conferences - Mar 03, 2022
3/3/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced its participation in three upcoming investor conferences.
-
Clover Selected for Inclusion on the Hang Seng Composite Index
2/24/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced that it has been selected for inclusion in the Hang Seng Composite Index as a constituent stock, effective March 7, 2022.
-
Clover Provides Corporate Update and 2022 Priorities
2/14/2022
Clover announces universal COVID-19 vaccine booster development plan to support global use of its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum).
-
Clover Appoints Nicholas Jackson, Ph.D., as President of Global Research and Development
2/1/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced the appointment of Nicholas Jackson, Ph.D., as President of Global Research and Development.
-
Clover’s Final SPECTRA Phase 2/3 Clinical Trial Efficacy Data Is Published in The Lancet
1/21/2022
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that final efficacy data from SPECTRA, a global Phase 2/3 clinical trial evaluating the efficacy, safety, and immunogenicity of its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), has been published in the peer-reviewed journal, The Lancet.